ERBB2 and neoplasm: The data from five clinical trials using trastuzumab in BC patients whose tumours overexpress HER2 ultimately led to the registration of trastuzumab in 1998 as the first anti-ErbB-targeted agent which has become nowadays the mainstay of therapy in HER2-positive BC (Perez et al. 2011).